• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静电作用驱动人干扰素 α-2a 的寡聚化和聚集。

Electrostatics Drive Oligomerization and Aggregation of Human Interferon Alpha-2a.

机构信息

Novozymes A/S, Bagsvaerd, 2880, Denmark.

Department of Chemistry, Technical University of Denmark, Kongens Lyngby, 2800, Denmark.

出版信息

J Phys Chem B. 2021 Dec 23;125(50):13657-13669. doi: 10.1021/acs.jpcb.1c07090. Epub 2021 Dec 13.

DOI:10.1021/acs.jpcb.1c07090
PMID:34898211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8713289/
Abstract

Aggregation is a common phenomenon in the field of protein therapeutics and can lead to function loss or immunogenic patient responses. Two strategies are currently used to reduce aggregation: (1) finding a suitable formulation, which is labor-intensive and requires large protein quantities, or (2) engineering the protein, which requires extensive knowledge about the protein aggregation pathway. We present a biophysical characterization of the oligomerization and aggregation processes by Interferon alpha-2a (IFNα-2a), a protein drug with antiviral and immunomodulatory properties. This study combines experimental high throughput screening with detailed investigations by small-angle X-ray scattering and analytical ultracentrifugation. Metropolis Monte Carlo simulations are used to gain insight into the underlying intermolecular interactions. IFNα-2a forms soluble oligomers that are controlled by a fast pH and concentration-dependent equilibrium. Close to the isoelectric point of 6, IFNα-2a forms insoluble aggregates which can be prevented by adding salt. We show that monomer is driven mainly by molecular anisotropic dipole-dipole interactions that increase with increasing pH. is due to monopole-monopole interactions and depends on the charge of IFNα-2a. The study highlights how combining multiple methods helps to systematically dissect the molecular mechanisms driving oligomer formation and to design ultimately efficient strategies for preventing detrimental protein aggregation.

摘要

聚集是蛋白质治疗领域的常见现象,可导致功能丧失或免疫原性的患者反应。目前有两种策略可用于减少聚集:(1)寻找合适的配方,这是一项劳动密集型工作,需要大量的蛋白质,或者(2)对蛋白质进行工程改造,这需要对蛋白质聚集途径有广泛的了解。我们通过干扰素 alpha-2a(IFNα-2a)对低聚物化和聚集过程进行了生物物理特性分析,IFNα-2a 是一种具有抗病毒和免疫调节特性的蛋白质药物。本研究将实验高通量筛选与小角 X 射线散射和分析超速离心的详细研究相结合。Metropolis 蒙特卡罗模拟用于深入了解潜在的分子间相互作用。IFNα-2a 形成可溶的低聚物,由快速 pH 和浓度依赖性平衡控制。在等电点 6 附近,IFNα-2a 形成不溶性聚集体,通过添加盐可以防止。我们表明,单体主要由分子各向异性偶极子-偶极子相互作用驱动,该相互作用随 pH 值的增加而增加。则归因于单极子-单极子相互作用,取决于 IFNα-2a 的电荷。该研究强调了如何结合多种方法有助于系统地剖析驱动低聚物形成的分子机制,并最终设计出有效防止有害蛋白质聚集的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/d58a467f24c9/jp1c07090_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/9c33eceaac9b/jp1c07090_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/8e9edfa9a43d/jp1c07090_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/b1637ff739ff/jp1c07090_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/3c600a82a112/jp1c07090_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/d2b6350eac7b/jp1c07090_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/376d03a192c8/jp1c07090_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/5574774ee74f/jp1c07090_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/ff62d784868a/jp1c07090_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/d58a467f24c9/jp1c07090_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/9c33eceaac9b/jp1c07090_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/8e9edfa9a43d/jp1c07090_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/b1637ff739ff/jp1c07090_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/3c600a82a112/jp1c07090_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/d2b6350eac7b/jp1c07090_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/376d03a192c8/jp1c07090_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/5574774ee74f/jp1c07090_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/ff62d784868a/jp1c07090_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b53c/8713289/d58a467f24c9/jp1c07090_0007.jpg

相似文献

1
Electrostatics Drive Oligomerization and Aggregation of Human Interferon Alpha-2a.静电作用驱动人干扰素 α-2a 的寡聚化和聚集。
J Phys Chem B. 2021 Dec 23;125(50):13657-13669. doi: 10.1021/acs.jpcb.1c07090. Epub 2021 Dec 13.
2
Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers.40 kDa聚乙二醇化干扰素α2a及其各个位置异构体的结构和生物物理特性
Bioconjug Chem. 2005 May-Jun;16(3):504-17. doi: 10.1021/bc049781+.
3
Antimicrobial preservatives induce aggregation of interferon alpha-2a: the order in which preservatives induce protein aggregation is independent of the protein.抗菌防腐剂会诱导α-2a干扰素聚集:防腐剂诱导蛋白质聚集的顺序与蛋白质无关。
Int J Pharm. 2014 Sep 10;472(1-2):356-61. doi: 10.1016/j.ijpharm.2014.06.044. Epub 2014 Jun 27.
4
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.聚乙二醇干扰素α-2a(40kD)(派罗欣)与干扰素α-2a(罗扰素)用于初治慢性期慢性粒细胞白血病患者的随机、多中心、II期对照研究
Leuk Lymphoma. 2007 Mar;48(3):497-505. doi: 10.1080/10428190601175393.
5
Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.聚乙二醇干扰素α-2a与干扰素α-2b联合利巴韦林作为慢性丙型肝炎患者初始治疗时的生活质量、工作效率及医疗资源利用情况比较
J Viral Hepat. 2004 Mar;11(2):157-65. doi: 10.1046/j.1365-2893.2003.00482.x.
6
Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2.40 kDa聚乙二醇化干扰素α2a及其各个位置异构体与受体IFNAR2细胞外结构域结合的结构、动力学和热力学分析。
Bioconjug Chem. 2005 May-Jun;16(3):518-27. doi: 10.1021/bc049780h.
7
Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.在对聚乙二醇干扰素α-2a无早期应答的慢性乙型肝炎患者中添加核苷类似物可增强病毒学应答:一项随机对照试验。
BMC Gastroenterol. 2017 Aug 30;17(1):102. doi: 10.1186/s12876-017-0657-y.
8
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗丙型肝炎病毒(HCV)慢性活动性肝炎无应答者的一项初步研究。
J Interferon Cytokine Res. 2008 Oct;28(10):623-9. doi: 10.1089/jir.2007.0116.
9
The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.聚乙二醇干扰素α-2a 和 α-2b 在慢性乙型肝炎患者中的疗效比较。
Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1312-6. doi: 10.1097/MEG.0b013e328362389a.
10
Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.聚乙二醇干扰素α-2a(40KD)联合利巴韦林治疗日本慢性丙型肝炎患者。
J Gastroenterol Hepatol. 2007 May;22(5):645-52. doi: 10.1111/j.1440-1746.2007.04834.x.

引用本文的文献

1
Synthetic T-Cell Receptor-like Protein Behaves as a Janus Particle in Solution.合成的类T细胞受体蛋白在溶液中表现为两面神粒子。
J Am Chem Soc. 2025 Jan 8;147(1):247-256. doi: 10.1021/jacs.4c08932. Epub 2024 Dec 19.
2
Collection of serum albumin aggregate nanoparticles from human plasma by dielectrophoresis.利用介电泳从人血浆中收集血清白蛋白聚集体纳米颗粒。
Electrophoresis. 2024 Oct;45(19-20):1748-1763. doi: 10.1002/elps.202400046. Epub 2024 Jul 30.
3
A multi-scale numerical approach to study monoclonal antibodies in solution.

本文引用的文献

1
Combination of high throughput and structural screening to assess protein stability - A screening perspective.高通量与结构筛选相结合评估蛋白质稳定性——筛选视角。
Eur J Pharm Biopharm. 2022 Feb;171:1-10. doi: 10.1016/j.ejpb.2021.08.018. Epub 2021 Nov 23.
2
The Effect of Point Mutations on the Biophysical Properties of an Antimicrobial Peptide: Development of a Screening Protocol for Peptide Stability Screening.点突变对抗菌肽生物物理性质的影响:肽稳定性筛选方案的开发
Mol Pharm. 2020 Sep 8;17(9):3298-3313. doi: 10.1021/acs.molpharmaceut.0c00406. Epub 2020 Aug 7.
3
Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
一种研究溶液中单克隆抗体的多尺度数值方法。
APL Bioeng. 2024 Feb 26;8(1):016111. doi: 10.1063/5.0186642. eCollection 2024 Mar.
4
Controlling the Quality of Nanodrugs According to Their New Property-Radiothermal Emission.根据纳米药物的新特性——辐射热发射来控制其质量。
Pharmaceutics. 2024 Jan 26;16(2):180. doi: 10.3390/pharmaceutics16020180.
5
Bovine Serum Albumin Rejection by an Open Ultrafiltration Membrane: Characterization and Modeling.开放式超滤膜对牛血清白蛋白的截留:表征与建模
Membranes (Basel). 2024 Jan 21;14(1):0. doi: 10.3390/membranes14010026.
通过全面的计算和生物物理特性分析来推进治疗性蛋白的发现和开发。
Mol Pharm. 2020 Feb 3;17(2):426-440. doi: 10.1021/acs.molpharmaceut.9b00852. Epub 2020 Jan 7.
4
Rapid sample-saving biophysical characterisation and long-term storage stability of liquid interferon alpha2a formulations: Is there a correlation?快速取样保存的生物物理特性分析及液体干扰素 α2a 制剂的长期储存稳定性:两者是否存在相关性?
Int J Pharm. 2019 May 1;562:42-50. doi: 10.1016/j.ijpharm.2019.03.025. Epub 2019 Mar 14.
5
2018 FDA drug approvals.2018年美国食品药品监督管理局批准的药物
Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
6
Biopharmaceutical benchmarks 2018.2018年生物制药基准
Nat Biotechnol. 2018 Dec 6;36(12):1136-1145. doi: 10.1038/nbt.4305.
7
HullRad: Fast Calculations of Folded and Disordered Protein and Nucleic Acid Hydrodynamic Properties.HullRad:折叠和无序蛋白质与核酸流体力学性质的快速计算。
Biophys J. 2018 Feb 27;114(4):856-869. doi: 10.1016/j.bpj.2018.01.002.
8
: a comprehensive data analysis suite for small-angle scattering from macromolecular solutions.用于大分子溶液小角散射的综合数据分析套件。
J Appl Crystallogr. 2017 Jun 26;50(Pt 4):1212-1225. doi: 10.1107/S1600576717007786. eCollection 2017 Aug 1.
9
Use of antiviral therapy in patients with chronic hepatitis C.慢性丙型肝炎患者抗病毒治疗的应用。
Open Med (Wars). 2015 Mar 20;10(1):209-215. doi: 10.1515/med-2015-0032. eCollection 2015.
10
, a program for rapid shape determination in small-angle scattering.用于小角散射中快速形状测定的一个程序。
J Appl Crystallogr. 2009 Apr 1;42(Pt 2):342-346. doi: 10.1107/S0021889809000338. Epub 2009 Jan 24.